Evaluation of optimal dosage of anesthetic

Evaluation of optimal dosage of anesthetic - Evaluation of optimal dosage of anesthetic

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011975

Enrollment

Registered

2013-10-10

Start date

2013-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arteriosclerosis obliterans ischemic heart disease valvular disease aneurysm of the aorta

Interventions

remifentanil1.0ug/kg/min,propofol2ug/ml remifentanil0.5ug/kg/min,propofol2ug/ml remifentanil0.5ug/kg/min,propofol3ug/ml

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were scheduled to undergo peripheral vascular bypass surgery for arteriosclerosis obliterans and patients who were scheduled to undergo cardiovascular surgery(coronary artery bypass grafting, valve replacement, or replacement of the aorta)

Exclusion criteria

Exclusion criteria: arrhythmia heart failure(EF<30%)

Design outcomes

Primary

Measure	Time frame
blood pressure	—

Countries

Japan

Contacts

Public ContactToyama Yuki

Asahikawa Medical University Department of Anesthesiology&Critical care

toyama12@asahikawa-med.ac.jp0166682583

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026